Novagali Pharma Completed a New Phase II With Cyclokat(R) in Dry Eye

EVRY, France - Novagali Pharma, a French pharmaceutical ophthalmic company, today announces successful completion of a new Phase II clinical study with Cyclokat(R), its formulation of Cyclosporine. The results demonstrate statistically significant improvement with signs and symptoms in patients suffering from moderate-to-severe dry eye syndrome.

Oasmia: FDA Grants Paclical(R) Orphan Drug Designation for Ovarian Cancer in the USA

UPPSALA, Sweden - Oasmia Pharmaceutical, Uppsala, Sweden, has been granted Orphan Drug designation by the USA FDA of Paclical(R) for the treatment of ovarian cancer. Orphan Drug designation can entail additional assistance from FDA to expedite and optimize drug development and upon approval a seven year market exclusivity is granted.

InSightec Ltd. Announces US$15 Million Investment Round

TIRAT CARMEL, Israel - InSightec Ltd. reported today that it has closed an internal round of
financing totaling US$15 million from its existing investors.

U.S. Food and Drug Administration Clears Way for Multi-Center Clinical Trial of IDEV Technologies’ SUPERA Peripheral Stent

HOUSTON - Novel Stent Platform Designed for Radial Strength, Flexibility

IDEV Technologies Incorporated, (IDEV) an emerging leader in the
development and marketing of minimally invasive technologies, announced today
that the U.S. Food and Drug Administration (FDA) has approved an
investigational device exemption (IDE) for a multi-center clinical trial of
its SUPERA stent, a novel stent platform designed for the treatment of
peripheral artery disease (PAD) in the superficial femoral artery (SFA). PAD
affects more than 8 million people in the U.S. alone and, by the age of 65,
12-20 percent of the population will develop PAD, according to the American
Heart Association.